BIOMED PHARMACOTHER 润色咨询

BIOMEDICINE & PHARMACOTHERAPY

出版年份：1982 年文章数：8228 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：10.8% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    11小时前 ms47000005263749 来自山东省


    前往app查看评论内容

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    15小时前 1474f621m51暂无昵称 来自青海省

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向：药理
    经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-16 ms9000000991394845 来自江苏省

    投稿命中率:50.0
    偏重的研究方向：肿瘤
    经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了

    4

    展开4条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-13 1489114dm38(暂无昵称) 来自四川省

    偏重的研究方向：肿瘤
    经验分享：4.25投稿，目前还在submitted阶段。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-20 ms7000001429012151 来自北京

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向：心血管
    经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-18 147fbbf2m68(暂无昵称) 来自四川省

    很高

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-17 ms7000000856963905 来自江苏省

    日均40+篇的投稿，太tm恐怖了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-04-23 ms4000001066891631 来自江西省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向：肝脏疾病;肿瘤
    经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？

    2

    展开2条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-03-08 chy 来自辽宁省

    记录一下，2.16投稿的，1300+，今天还是Submitted to journal

    14

    展开14条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2205907, encodeId=aa46220590ef5, content=前往app查看评论内容, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7e18595630, createdName=ms47000005263749, createdTime=Tue May 21 20:48:41 CST 2024, time=11小时前, status=0, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2205869, encodeId=572922058698b, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向：药理<br>经验分享：人生第一篇SCI ，4月初投稿，5.17让小修，5.20递交，当天接收。非常nice , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/12/0d585ea4b4220bf6db12a023df297172.jpg, createdBy=4c825206819, createdName=1474f621m51暂无昵称, createdTime=Tue May 21 16:39:46 CST 2024, time=15小时前, status=1, ipAttribution=青海省), GetPortalCommentsPageByObjectIdResponse(id=2205009, encodeId=aace220500909, content=投稿命中率:50.0<br>偏重的研究方向：肿瘤<br>经验分享：5-6投稿，4028，现在5-16，还没到编辑手里，麻木了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04316547419, createdName=ms9000000991394845, createdTime=Thu May 16 12:01:29 CST 2024, time=2024-05-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2204506, encodeId=edfd2204506ed, content=偏重的研究方向：肿瘤<br>经验分享：4.25投稿，目前还在submitted阶段。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72535313351, createdName=1489114dm38(暂无昵称), createdTime=Mon May 13 18:40:09 CST 2024, time=2024-05-13, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205756, encodeId=bc852205e56da, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向：心血管<br>经验分享：想问一下，这个杂志必须WB要每一张膜提供三次重复的膜吗？我每组至少都是n=3但是在一张膜上可以吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e209039969, createdName=ms7000001429012151, createdTime=Mon May 20 23:06:52 CST 2024, time=2024-05-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2205335, encodeId=f1b32205335ac, content=很高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e61b5259412, createdName=147fbbf2m68(暂无昵称), createdTime=Sat May 18 09:39:52 CST 2024, time=2024-05-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2205201, encodeId=d56f220520199, content=日均40+篇的投稿，太tm恐怖了<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18898386622, createdName=ms7000000856963905, createdTime=Fri May 17 15:04:05 CST 2024, time=2024-05-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2200036, encodeId=73b2220003682, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向：肝脏疾病;肿瘤<br>经验分享：啊啊啊找不到审稿人，已经陆陆续续邀请21个了 under review了20天还没人审稿 大家都是多久找到审稿人的呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74479171808, createdName=ms4000001066891631, createdTime=Tue Apr 23 21:50:52 CST 2024, time=2024-04-23, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2192087, encodeId=2e7d219208ead, content=记录一下，2.16投稿的，1300+，今天还是Submitted to journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=aa0b5490731, createdName=chy, createdTime=Fri Mar 08 14:54:38 CST 2024, time=2024-03-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2201387, encodeId=9fbc220138e00, content=偏重的研究方向：分子机制<br>经验分享：今天刚投，现在3860，请问大家到编辑手里要多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34f28143089, createdName=ms7000001457628064, createdTime=Wed May 01 17:23:17 CST 2024, time=2024-05-01, status=1, ipAttribution=四川省)]
    2024-05-01 ms7000001457628064 来自四川省

    偏重的研究方向：分子机制
    经验分享：今天刚投，现在3860，请问大家到编辑手里要多久

    3

    展开3条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分